1. GSK takes RSV maternal vaccine candidate into phase 3 testing — FDA approves Alnylam's first-ever drug for rare kidney disease — FDA approves Roche's Xofluza to prevent flu spreading within families — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Abbott Neuromodulation

Discussion in 'Abbott' started by anonymous, Jun 6, 2018 at 12:50 PM.

  1. anonymous

    anonymous Guest

    So what?
     

  2. anonymous

    anonymous Guest

    LOL! Flat sales for Abbott neuromod in Q4 - in a sector that is growing in mid-double digits. Boston is now officially dominating them. Not surprised with the culture that they created in Austin. Two more people left the marketing team in the last quarter.
     
  3. anonymous

    anonymous Guest

    That's crazy! My financial advisor just told me that Boston Scientific Neuromodulation had 18% revenue growth during the same period. Looks like the exorbitant physician payments just can't make up for bad marketing anymore...
     
  4. anonymous

    anonymous Guest

    Yah, I just heard that the VP of Marketing, Chris Bingham, got fired this week. With more turnover expected...
     
  5. anonymous

    anonymous Guest

    You SJM slouches are lucky Abbott bailed your ass out. Nobody gives a shit about how the game is played. You’re on the sidelines and helpless. That $500k returned $10M easy. ADC dreads you SJM meter maids. Big business for Abbott and White knows the market. We’re gonna destroy BSX in due time. This better not be you Brinkman.
     
  6. anonymous

    anonymous Guest

    9% decline in sales in Q1 year over year - in a market where the competitors are growing at a double-digit rate... The chickens have finally come home to roost and the Abbott neuromodulation division is paying a huge price for the arrogance in upper management. You would think that changes in the senior management group are imminent after 3 dismal quarters, but Miles White is between a rock and a hard place. He can't fire Keith Boettiger, as he does not know anything about neuromodulation. At the same time, he might have an investor revolt on his hands if he does not get more out of a division where market growth is above 10% per year. The Q1 '19 results will probably force his hand. Or hopefully - not sure I want stock in a company where executive leadership can't make simple calls like this. The rot starts at the top.
     
  7. anonymous

    anonymous Guest

    Is that right? I just had an interview with Boston Scientific and supposedly they grew 10% yoy during the same time. Abbott must really be struggling!
     
  8. anonymous

    anonymous Guest

    probably because they hire girls based on looks and marital status as opposed to having any solid experience in pain management.
     
  9. anonymous

    anonymous Guest

    i hooked up with two reps in Las Vegas. one from Chicago, the other from FLA.
     
  10. anonymous

    anonymous Guest

    LOL! Right on! More power to you. Sounds like they are hiring great "talent" after all. On a serious note, employees in the neuromodulation division should start a "Fire Boettiger" petition to save their careers...
     
  11. anonymous

    anonymous Guest

    The freefall is now official. Abbott Neuromodulation sales declined almost 5% year over year in Q2 - in a market that is growing at mid-double digits. I guess Mr. Boettiger was always worried about getting taken seriously. I guess he can stop worrying now...
     
  12. anonymous

    anonymous Guest

    Hey at least they re launched proclaim 5 with all the Neuromod “young guns”
    Jerking each other off on social media with the one Bold IPG they will put in and then go back to the better product they were using.
     
  13. anonymous

    anonymous Guest

    Can’t wait for these reps to get prosecuted. You won’t even be able to get a job in pharma when this is over lol
     
  14. anonymous

    anonymous Guest

    Bwahahahaha! Did I see correctly that ABT neuromod sales declined almost 3% year over year in the Q3 earnings announced last year? Medtronic, BSC and Nevro must be raking it in! Yet ABT continues with the same washed up airbags in upper management. What's the definition of insanity again? On the bright side, I guess the comps are looking good for some renewed posturing in 2020...
     
  15. anonymous

    anonymous Guest

    You were Duncan and Carl’s bitch, and got slapped!
     
  16. anonymous

    anonymous Guest

    Abbott sees Nevro as a small player who cannot make a dent in Neuromod sales - and if they do, Abbott can buy Nevro ... or so management believes
     
  17. anonymous

    anonymous Guest

    Abbott Neuromod sales declined 4% yoy in 2019 and Nevro’s market cap went from $1.2B to $4.2B during the same time. Looks like Nevro is kicking Abbott’s ass!
     
  18. anonymous

    anonymous Guest

    Abbott Neuromod is a clown show. 10% DECLINE yoy in sales in Q1. Nevro and BSX are legitimately mopping the floor with this division. I guess renaming Proclaim 3 times ended up not being a good long term marketing strategy...
     
  19. anonymous

    anonymous Guest

    Why did they rise and decline so rapidly? Is there a future there now that Nevro’s market cap crossed $5B?
     
  20. anonymous

    anonymous Guest

    Horrible culture - led by Mr. Boettiger. Once the commissions dried up, so did one of the last remaining reasons to stay. Nevro, Boston and Medtronic are all leapfrogging them. Not much of a future left at Abbott Neuromodulation.